|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
MNTA Analysis & Videos »
MNTA: Bull or Bear?
FDA Calendar Extreme Trades: 85 Single Digit Stocks
MNTA
|
|
|
+48.84%
in
1344 days
<> <> The <font> BioMedReports.com FDA Calendar database </font> includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results. My FDA Calendar Extreme Trades article series highlights companies with market caps below $1 billion and / or single digit stock prices with pending catalysts in the form of FDA decisions, clinical trial res...
|
Momenta Pharma: Timing Uncertain, Approval Likely for M-Enoxaparin
MNTA
|
|
|
+0.85%
in
7 days
(closed on 10/13/09)
Momenta Pharma (NASDAQ: MNTA) presented at the 2009 UBS Global Life Sciences Conference about two weeks ago and outlined several key developments for the Company, including an update on the FDA status for M-Enoxaparin. <o:p> </o:p> <o:p> </o:p> <> <> In late September, the Company raised net proceeds of approximately $46.7 million through a public offering of 4.6 million shares of common at $10.75 per share (compared to a current share price hovering around $9.50). Momenta provided guidance for ending the year with about $90-100 million in cash, providing adequate liquidi...
|
BioMed News Bytes: Arena (NASDAQ: ARNA), Momenta (NASDAQ:MNTA), Vivus (NASDAQ: VVUS)
MNTA
|
|
|
-18.08%
in
18 days
(closed on 10/06/09)
<> On 9/18/09, Arena Pharma (NASDAQ: ARNA) ($5.32, +9%) (heavy, above-average volume) announced lorcaserin met all primary endpoints and FDA benchmark with 63% of patients who complied with the protocol losing at least 5% of their weight. ARNA plans to file a NDA with the FDA in December. However, patients who took lorcaserin 10 mg twice daily achieved an average weight loss of 5.9% of their body weight, compared to 2.8% for placebo, causing shares of ARNA to initially decline on the news (with a recent turnaround and uptick) based on concerns for the commercial prospects of lorcaserin compar...
|
FDA Declines to Review Teva's Citizen Petition for Copaxone
MNTA
|
|
|
+3.15%
in
160 days
(closed on 09/18/09)
Source: FDANews.com. The FDA has declined to review a citizen petition submitted by the neuroscience division of Teva Pharma (TEVA) asking the agency not to accept applications for generic versions of the Copaxone multiple sclerosis treatment until certain conditions are met. The agency told Teva that it would be “premature and inappropriate” to review the Copaxone (glatiramer acetate) petition filed last September. In addition, the FDA didn’t address or take action on Teva’s requests in the petition, the company says in a statement. <> <> <>http://biomedreports.com/articles/la...
|
Opinion: Pathway for FOBs Should Balance Need for Competition and Need for Innovation
MNTA
|
|
|
+39.52%
in
28 days
(closed on 04/09/09)
This story was written by James Bianco, M.D., prinicipal founder, CEO, and director of Cell Therapeutics (CTIC), which is a member of the ETF Innovators Emerging Bio-Pharma Index: Related Article on Momenta Pharma (MNTA) by Mike Havrilla: <> President Obama's first budget calls for the creation of a regulatory pathway for the creation of follow-on, or biosmiliar, biologics. This is obviously now the most hi...
|
Three Oversold Healthcare Catalyst Stocks
MNTA
|
|
|
+9.33%
in
23 hours
(closed on 03/12/09)
With the S&P 500 SPDR ETF (SPY) trading about 8% below its 50-day moving average (DMA), I went in search of oversold healthcare stocks trading at least 16% below their 50 DMA which have potential catalysts within the next six months that may provide some very nice returns. <> The Healthcare Sector SPDR (XLV) is trading about 12% below its 50 DMA amidst concerns of sweeping healthcare reform that would threaten the profits of health insurers, managed care companies, big pharma, and biotechs – although such concerns may be overblown given the failed attempts at large scale healthc<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Momenta Pharma's Three-Part Strategy
MNTA
|
|
|
-0.95%
in
6 days
(closed on 03/12/09)
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB). http://www.biomedreports.com/blog/Momenta-Pharmas-Three-Part-... <> <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awa...
|
Big Pharma Goes Generic
MNTA
|
|
|
-29.64%
in
8 days
(closed on 03/06/09)
<> <> <> <> <> <>  Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
|
Healthcare Hot Spots Beyond Stem Cells
MNTA
|
|
|
-2.97%
in
31 days
(closed on 02/26/09)
Beyond Stem Cells: Healthcare Hot Spots With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM). <> Below are three additional areas and associated companies for investors to consider in the search of the next hot s...
|
Trading FDA Decisions: CYPB Soars, A Trio of Buys
MNTA
|
|
|
-1.19%
in
12 days
(closed on 01/26/09)
Trading FDA Decisions: CYPB Soars, A Trio of Buys After the market close today, Cypress Bioscience (CYPB) and Forest Labs (FRX) received FDA approval for Savella (milnacipran) in the treatment of fibromyalgia, almost exactly three months after the original PDUFA date of 10/18/08. Shares of CYPB are soaring into double digits (up over 50%) while FRX is up 10% in after hours trading at just after 6 pm ET. <> Meanwhile, Schering Plough (SGP) was not as fortunate, as the company received a complete response letter for schizophrenia drug Saphris (asenapine). Howe...
|
20 Emerging Healthcare Stocks to Watch in '09
MNTA
|
|
|
-0.37%
in
4 days
(closed on 01/14/09)
<> As a follow-up to my most recent article on the buyout binge among bio-pharma and diagnostic companies, below is a basket of 20 stocks (listed randomly) to consider from the ETF Innovators Indexes of 250 companies which represent a mix of pending catalysts in the form of clinical trials or FDA decisions, innovative patent portfolios or drug discovery technology platforms, promising compounds in clinical development, and marketed therapeutic or diagnostic products. Click on any of the company names for links to all of my prev...
|
Nine for '09 Stock Picks Start Strong
MNTA
|
|
|
-7.28%
in
2 days
(closed on 01/10/09)
<> 
The nine stock picks I posted in mid-December are off to a strong start in the new year, with seven of the stocks registering gains and a 14.5% gain for the group as an equal-weight average versus a 1.1% gain for the S&P 500 SPDR ETF (SPY). Click on any of the links below for my most recent articles on each company.
The four smallest, defensive healthcare stock picks are leading the group with an average gain of 30.6% thanks to an 87.3% gain for Javelin Pharma (JAV) and a 42.9% gain for Caraco Pharma (CPD) while...
|
Momenta Pharma: A Pure Play on Bio-Generics
MNTA
|
|
|
+4.88%
in
4 days
(closed on 01/08/09)
Momenta Pharma (MNTA) represents a pure play investment for the future of bio-generics, with two ANDAs filed at the FDA in partnership with the Sandoz division of Novartis (NVS) for multi-billion dollar biological agents Lovenox ($3.8B in sales for 2007) (blood thinner) – Sanofi-Aventis (SNY) and Copaxone ($1.7B in sales for 2007) (multiple sclerosis) – Teva Pharma (TEVA). However, it is important to note that the ANDAs for Lovenox and Copaxone can be approved through existing pathways at the FDA and do not require the passage of legislation to make it on the market. <> Incl...
|
My UpDown Virtual Investing Portfolio
MNTA
|
|
|
-2.93%
in
3 days
(closed on 01/04/09)
<> 
Start earning real money with zero risk while improving your trading skills and strategies at the UpDown Virtual Investing website -- just click on the image above or any of the text links to the site in this article to sign up today. My stats and profile are featured in the accompanying table and on my blog site below the last posted entry. I started trading at the UpDown on 11/23/08 with a gain of 32.5% through today -- my profile name on the site is 'ETFinnovators' with a portfolio of long positions and link...
|
People Bullish on MNTA
People Bearish on MNTA
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on MNTA |
More Resources
|
About Momenta Pharmaceuticals Inc.
- Answers.com
